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Abstract
Introduction: Underestimation of the actual blood loss in patients undergoing nontraumatic transfemoral amputation (TFA) can
impact negatively on outcome in these often frail patients, with very limited physiological reserves. The primary aim of this study is
to estimate the total blood loss (TBL) after TFA, and second, to evaluate the impact of blood loss on 30-day mortality and medical
complications. Methods: A single-center retrospective cohort study conducted from 2013 to 2015. The TBL was calculated on
the fourth postoperative day. It was based on the hemoglobin levels, transfusions, and the estimated blood volume. Results:
Eighty-one patients undergoing TFA were included for final analysis. The median TBL was 964 mL (interquartile range [IQR]: 443-
1558). The intraoperative blood loss (OBL) was 400 mL (IQR: 200-500). The median difference between TBL and OBL was 688
mL (IQR: 124-1075). The patient received red blood cell (RBC) transfusion of a median amount of 2 units. Higher number of
transfusions (>2) did not impact the outcome. From multivariable analysis, it was evident that the TBL increased significantly in
patients with renal disease prior to surgery, (P ¼ .034). The TBL itself was not independently associated with increased 30-day
mortality or medical complications. Conclusion: The TBL after TFAs is significantly greater than the volume estimated
intraoperatively and increases significantly in the presence of renal disease prior to surgery. An increased TBL and requirement for
RBC transfusion is not directly associated with 30-day mortality or medical complications. A high vigilance for anemia seems
advisable when planning for TFA surgery. Research on optimum blood conservation and transfusion strategies during TFA is
warranted.
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Introduction
Patients requiring transfemoral amputation (TFA) on the basis
of atherosclerosis or diabetes mellitus are often fragile, old, and
with several comorbidities.1,2 They pose a challenge to all
medical staff involved in the treatment due to their limited
physiological reserves. The total blood loss (TBL) associated
with TFA surgery has, to our knowledge, never been investi-
gated. Due to their limited physiological reserves, these
patients are at increased risk of reduced organ perfusion and
subsequent ischemia, organ failure, and death as a consequence
of anemia.1
The primary aim of this study is to quantify the TBL in the
perioperative period until the fourth postoperative day and the
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potential related predictors. Second, since medical complica-
tions and 30-day mortality are high during the early phase after
TFA, the TBL and the red blood cell (RBC) transfusion amount
are to be investigated as potential contributors.
Patients and Methods
Study Population
Between January 2013 and March 2015, a total of 150 consec-
utive TFA procedures were studied. Through a systematic
search of our institutional surgical database, we extracted the
demographic baseline and postoperative parameters of interest.
Patients were included if the indication for surgery was severe
atherosclerosis with pain or diabetes-related complications.
Only patients with a primary TFA were included. We excluded
patients who had undergone bilateral procedures, in whom
intramedullary nails were removed as part of the procedure,
who previously underwent lower extremity amputation surgery
on ipsilateral or contralateral extremity, who had clinical signs
of gastrointestinal bleeding (melena or hematemesis), who
used pneumatic tourniquet, and with missing data, including
patients who died before final Hgb at day 4. The study was
approved by the local ethics committee and registered at the
regional data protection agency (December 04, 2012; j. no.
01975 HVH-2012-053).
Procedure
The patients were treated in a dedicated amputation unit within
the department, regardless of their preoperative status. The
amputation unit uses a multimodal treatment and rehabilitation
program.3 This includes consultation with the department of
vascular surgery and the supplementary measurement of skin
perfusion pressure to determine the level of amputation. The
patients received general or neuroaxial anesthesia and antibio-
tics preoperatively and low-molecular-weight heparin after sur-
gery as prophylaxis against thromboembolism. The procedure
was performed approximately 10 cm above the knee joint and
with anterior and posterior skin flaps. Trained residents or
senior consultants performed the surgical procedures. Standar-
dized fluid and transfusion procedures were followed. Blood
loss was replaced with isotonic saline at a rate of 1:1 until the
level of hemoglobin fell below 9.67 g/dL (6 mmol/L), at which
point RBC transfusion was initiated. Postoperative fluid ther-
apy and intravenous fluids were only administered if the
patient’s oral intake was less than 2000 mL daily or if they
were hypovolemic. The level of hemoglobin was measured on
admission, prior to operation (less than 1 day before surgery),
and every morning until the fifth postoperative day. If a patient
received transfusions prior to surgery, a new hemoglobin mea-
surement was done hours afterward. The final hemoglobin
value was defined as the last sample obtained on the fourth
postoperative day. In the event of transfusion on day 4, the
hemoglobin value on day 5 was used instead.
Collection of Data
The variables of interest were collected retrospectively, along
with the 30-day mortality and medical complications. The
patients included were not weighed on a conventional scale
until the first postoperative day. The anesthesiologists esti-
mated patient weight prior to surgery supported by the patient’s
own information. The regular use of nonsteroidal anti-
inflammatory drugs (NSAIDs) or acetylsalicylic acid in any
dose, as well as the regular use of clopidogrel or vitamin K
antagonists before the amputation, was recorded. The use of
vasopressor drugs during surgery was also recorded. Medical
complications were defined as the occurrence of any of the
following: acute renal failure (RIFLE consensus definitions),4,5
deep venous thrombosis, myocardial infarction, pneumonia,
pulmonary embolism, sepsis, and stroke.
Blood Loss
The TBL was calculated using the Nadler approach,6,7 based on
the difference between the preoperative and fourth postopera-
tive day Hgb, the number of RBC transfusions, and the esti-
mated blood volume. The approach has been applied in total
hip/knee arthroplasty surgery and hip fracture surgery.7,8 The
intraoperative blood loss (OBL) was evaluated by the weight
difference in surgical swabs and the measured suction loss. The
blood volume was determined according to body mass, height,
and gender. The following formulas were used for calculation:
Blood volumeðlÞ ¼ heightðmÞ3  0:356þ weightðkgÞ
 0:033þ 0:183 for women;
Blood volumeðlÞ ¼ heightðmÞ3  0:367þ weightðkgÞ
 0:032þ 0:604 for men:
The formula used was as follows:
Hgbloss ¼ blood volume ðHgbadm  HgbfinÞ
þ Hgb transfusion;
where Hgbloss is the calculated total Hgb loss (g), Hgbadm is the
Hgb value on admission, Hgbfin is the final recorded Hgb value
on day 4, and Hgbtrans is the total amount of Hgb (g) in the
transfused RBCs before the measurement of Hgbfin. The blood
loss was estimated using the following formula:
Blood loss in mL ¼ ðHgbloss=HgbadmÞ  1000:
Statistical Analysis
Continuous data are presented as median values with inter-
quartile range (IQR) or mean values with standard deviations.
Categorical data are presented as numbers and percentages.
Preoperative data, with known influence on the TBL in other
orthopedic subspecialties,7,8 are analyzed in a multivariable
linear regression analysis. The medical complications and
30-day mortality in relation to TBL and transfusion requirements
are analyzed by multivariable logistic regression. The level of
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significance is set at P < .05. All analyses were performed
using IBM SPSS Statistics version 22.
Results
Of the 150 consecutive amputations accessible for inclusion, 81
patients met the inclusion criteria and were included in the final
analysis. In total, 69 TFAs were excluded due to reamputation
(36), bilateral procedure (12), use of pneumatic tourniquet (11),
gastrointestinal bleeding prior to surgery (5), lack of data due to
death before day 4 (4), and amputation in relation to removal of
an intramedullary nails (1). The preoperative demographics are
presented in Table 1. The patients were weighed on a conven-
tional scale the day after amputation. This was possible in 50%
of the cases. The average difference in weight compared to the
estimated weight before surgery was 8.0 kg. The daily Hgb
measurements were at no point below 10 g/dL on average.
The median TBL was 964 mL (IQR: 443-1558) and the
OBL 400 mL (IQR: 200-500). The median delta value between
TBL and OBL was 688 mL (IQR: 124-1075). In total, a median
of 2.0 (IQR: 1-3) units of RBC transfusion were administered
per patient from surgery until the fourth postoperative day.
Preamputation treatment with NSAID or acetylsalicylic acid,
duration of surgery, and cardiovascular or renal comorbidities
were all associated with an increased TBL in univariable anal-
ysis (Table 2). When a multivariable analysis was performed,
only the variable renal disease (P ¼ .034) was associated with
an increased TBL (Table 2).
Total blood loss per 100 mL and RBC transfusion amount
exceeding 2 units (n ¼ 27) showed no statistically significant
influence on medical complications or perioperative mortality
(Table 3). In all, 7 of the 15 patients who died had registered
medical complications prior to their death; 3 of them received
more than 2 units of RBC transfusion.
In total, 22 patients were amputated due to diabetes-related
complications. Nine of them had postoperative complications
(41%). In total, 52 patients were amputated due to atherosclero-
tic complications and 16 had postoperative complications
(31%). We expect some overlap between the group with
Table 1. Details on the Transfemoral Amputations.a
Sex (female/male) 42/39
Age, years, mean (SD) 76.8 (11.2)
Body mass index, mean (SD) 24.0 (7.5)
Cause of amputation
Diabetes/atherosclerosis/other 22/52/7
ASA groups, 1-2/3-4 10/71
Poor preamputation functional level (new mobility
score 0-5 )
78%
Preamputation nursing home residence/other hospital
department
23%/17%
Duration of surgery, minutes (SD) 78.2 (16.7)
NSAIDs or acetylsalicylic acid (yes) 44
Clopidogrel (yes) 22
Cardiovascular disease 14
Renal disease 20
Diabetes 29
Patients with >2 units of RBC transfusion 27
Patients with Hgb <9.67 g/dL prior to surgery 16
Delta Hgb 20% (presurgery to day 4 postsurgery) 15
Abbreviations: ASA, American Society of Anesthesiologists; HGB, hemoglobin;
NSAIDs, nonsteroidal anti-inflammatory drugs; RBC, red blood cell;
SD, standard deviation.
an ¼ 81.
Table 2. Univariable and Multivariable Linear Regression
of Predictors of Increased Total Blood Loss.
Estimate
(mL) 95% CI P Value
Univariable linear regression
Age, per year older 15 0.9 to 29.3 .064
Sex, male 223 124 to 569 .205
Body mass index, per 1 unit 3.5 20 to 27 .969
Charge of surgeon, senior
consultant
40 433 to 353 .840
Duration of surgery, per
minute
15 5 to 25 .005
NSAID/magnyl, yes 473 126 to 819 .008
Clopidogrel, yes 43 473 to 387 .842
Cardiovascular comorbidity,
yes
521 73 to 969 .023
Diabetes, yes 102 263 to 466 .580
Renal disease, yes 564 169 to 958 .006
Multivariable linear regression
Age, per year older 12 6 to 29 .190
Sex, male 200 152 to 552 .260
Body mass index, per 1 unit 1 25 to 24 .954
Charge of surgeon, senior
consultant
121 513 to 271 .540
Duration of surgery, per
minute
11 1 to 23 .075
NSAID/magnyl, yes 401 6 to 808 .053
Clopidogrel, yes 62 449 to 573 .809
Cardiovascular comorbidity,
yes
209 272 to 691 .388
Diabetes, yes 169 612 to 274 .449
Renal disease, yes 489 38 to 940 .034
Abbreviation: NSAIDs, nonsteroidal anti-inflammatory drugs.
Table 3. Medical Complication or 30-Day Mortality in Relation to
TBL per 100 mL and RBC Transfusions >2 Units.
Multivariable Logistic Regression
Variable Estimate 95% CI P Value
TBL, per 100 mL 0.979 0.893-1.075 .660
>2 Units of RBC transfusion (yes) 1.774 0.367-8.569 .476
Preoperative anemia, (yes) 4.525 0.882-23.213 .070
Age, per year 0.959 0.906-1.015 .146
Sex, male 3.512 1.065-11.583 .039
Duration of surgery, per minute 1.039 0.995-1.085 .081
Charge of surgeon, senior
consultant
0.773 0.212-2.821 .697
Thrombocyte inhibitors, (yes) 0.588 0.165-2.097 .413
Renal disease, (yes) 1.109 0.290-4.247 .880
Abbreviations: RBC, red blood cell; TBL, total blood loss.
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diabetes-related complications and the patients in the group
with atherosclerosis. The following results are only indicative.
There were no significant difference between the 2 subgroups
regarding TBL (P ¼ .841), the OBL (P ¼ .748), or complica-
tion rates (P ¼ .431).
Discussion
From this study, it seems warranted to conclude that the TBL in
relation to TFA is significantly higher than the amount
recorded by the operating surgeon. One should expect a higher
TBL when the patient presents with renal comorbidity. In this
study, an increased TBL and RBC transfusion rate above 2
units did not have a statistically significant impact on the 30-
day mortality or medical complications.
The TFA patients are, most likely, the patients with the
highest 30-day mortality, within orthopaedic surgery. In this
study, 88% of the patients were coded with American Society
of Anesthesiologists (ASA) score 3 to 4, and 30-day mortality
was 18.5%. In comparison to patients with Danish hip fracture,
which we consider the best match for the TFA population, only
58% of the patients with hip fracture were coded with (ASA
score, 3-4) and with a perioperative mortality of 13%.7 This
clearly underlines the vulnerability of these patients and serves
to remind us of how the continuous optimization of treatment
protocols is important.
The calculated TBL is an alternative way to approach the
bleeding in relation to surgery. From the study of patients with
hip fracture and using a similar approach, it was understood
that “the total blood loss is much greater than that observed
intraoperatively and frequent postoperative measurements of
hemoglobin are necessary to avoid anemia.”7(p1053) In regard
to the TFA procedure, there still remains a lack of knowledge
regarding the actual scope of the blood loss. The results of this
study showed TBL is approximately twice the amount of blood
loss recorded just after the surgical procedure. The most obvi-
ous reasons for this difference are diffuse hematomas occurring
postoperatively and an underestimation of the OBL by the
operating surgeons. This underestimation is described in other
orthopedic subspecialties, and it also seems to be a potential
factor in TFA surgery.9 The postoperative bleeding into the soft
tissues could be a result of insufficient hemostatic control of
minor vessels, in combination with seepage from the femur
canal after the femur is divided. Based on univariate analysis,
there was an association between increased TBL and the dura-
tion of surgery, renal or cardiovascular disease, and the treat-
ment with NSAIDs/acetylsalicylic acid. The most pronounced
impact is when a patient has renal disease prior to surgery, and
this remains the only statistically significant variable according
to multivariable regression analysis (Table 2). These patients
(n ¼ 20) have a TBL of 1288 mL (IQR: 791-2303). Little is
known about perioperative management of platelet dysfunction
associated with renal disease, but the finding of increased blood
loss is consistent with other studies.7,10,11
Anticoagulation therapy with low-molecular-weight heparin
was standard for all TFAs, and therefore, we cannot comment
on the impact on the TBL. However, the TBL in this study is of
such magnitude that it may be warranted to evaluate different
anticoagulant regimes.
The TBL had no direct association with perioperative medi-
cal complications and the 30-day mortality. This study illumi-
nates how often the patients receive RBC transfusions which is a
potential proxy for the deleterious effects of anemia.12,13 Other
departments may have other experiences regarding this amount
since it depends on the chosen transfusion trigger. It is acknowl-
edged that patients benefit from a liberal perioperative transfu-
sion strategy,12 especially when patients have some degree of
cardiovascular disease prior to surgery.14 A liberal transfusion
trigger of 9.67 g/dL (6 mmol/L) was therefore used to standar-
dize transfusion therapy and to minimize the potential effects of
anemia on the postoperative outcome. We did not find a transfu-
sion rate above the median 2 units to be associated with an
increased 30-day mortality or medical complications, which
could be due to a reduced impact of blood loss within a setting
of high anemia vigilance and a liberal transfusion policy.
Limitations
The change in blood volume over time when an extremity is
removed is considered a challenge in this study. This could
affect the calculated TBL, which depends entirely upon the
accuracy of the presurgery Hgb, the final Hgb values, and the
estimated blood volume. In order to assess the impact of a
reduced weight and thereby blood volume after amputation,
the patient’s weight after amputation was measured on a con-
ventional scale on the first postoperative day. As noted in the
results section, the average weight difference before and after
surgery was 8 kg. Since the weight difference is relatively
small, by taking into account the removal of the amputated
limb, it seems that the weight issue has a limited influence on
the results. We find it acceptable not to attempt to integrate
the weight change into the formula. The potential dehydration
when blood work is performed is also a source of biased
results; however, the patients included in this study followed
a strict fluid therapy protocol, and we believe the influence is
minimal. We did exclude a large number of patients in an
effort to obtain the most accurate estimation of blood loss
during TFA. It did not make sense to us to include patients
with secondary bleeding disorders or a procedure that deviates
from the standard operation protocol. However, we do
acknowledge that this approach could potentially lead to
selection bias. A future prospective study with a larger num-
ber of patients should be performed to understand the real
influence of TBL on mortality and also to ensure that com-
plications are not overlooked.
In conclusion, TBL calculated on day 4 after TFA surgery is
up to twice the amount of that observed during a surgical pro-
cedure. Patients having renal disease prior to amputation are
more likely to have an increase in TBL. The TBL did not
significantly influence the 30-day mortality or medical com-
plications, nor did an RBC transfusion amount >2 units. There-
fore, a high anemia vigilance is recommended when planning
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for TFA surgery. Further knowledge of the coagulation deficit,
platelet dysfunction, and possible treatment mechanisms in
patients with renal failure presenting for surgery is warranted
together with research on optimum blood saving and transfu-
sions strategies in TFA.
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